Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
A Study of Zidovudine in the Prevention of HIV Infection in Individuals Exposed to the Virus
- Conditions
- Locations
- 🇺🇸
Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States
A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 15
- Registration Number
- NCT00000742
- Locations
- 🇺🇸
Univ. of Rochester ACTG CRS, Rochester, New York, United States
🇺🇸Washington U CRS, Saint Louis, Missouri, United States
🇺🇸USC CRS, Los Angeles, California, United States
A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 60
- Registration Number
- NCT00000754
- Locations
- 🇺🇸
Alabama Therapeutics CRS, Birmingham, Alabama, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸Ucsd, Avrc Crs, La Jolla, California, United States
Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 36
- Registration Number
- NCT00000695
- Locations
- 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸Northwestern Univ Med School, Chicago, Illinois, United States
The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 52
- Registration Number
- NCT00000967
- Locations
- 🇵🇷
Univ. Hosp. Ramón Ruiz Arnau, Dept. of Peds., Bayamon, Puerto Rico
🇺🇸St. Jude/UTHSC CRS, Memphis, Tennessee, United States
🇵🇷San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico
Pilot Study to Evaluate the Efficacy of Zidovudine in Preventing CD4+ Lymphocyte Decline in Patients With Primary HIV Infection. (One Treatment Arm Receives Placebo)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 80
- Registration Number
- NCT00000765
- Locations
- 🇺🇸
Univ of Illinois, Chicago, Illinois, United States
🇺🇸Univ of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States
🇺🇸Houston Clinical Research Network, Houston, Texas, United States
The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 300
- Registration Number
- NCT00001087
- Locations
- 🇺🇸
Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
🇺🇸Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 200
- Registration Number
- NCT00002369
- Locations
- 🇵🇷
San Juan AIDS Program, Santurce, Puerto Rico
🇺🇸Boston Univ Med Ctr Hosp / Evans - 556, Boston, Massachusetts, United States
🇺🇸HIV Clinical Research Ctr, Fort Lauderdale, Florida, United States
A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 200
- Registration Number
- NCT00002168
- Locations
- 🇺🇸
Univ of Nebraska, Omaha, Nebraska, United States
🇺🇸Anderson Clinical Research, Washington, District of Columbia, United States
🇵🇷Hosp Regional de Ponce - Area Vieja, Ponce, Puerto Rico
A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-09-30
- Target Recruit Count
- 1600
- Registration Number
- NCT00000751
- Locations
- 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States
🇺🇸Univ of Massachusetts Med School, Worcester, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.